Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

In this RCT (n=567), bimekizumab was more effective than ustekinumab and placebo in terms of achievement of PASI90 at week 16 (85% versus 50% and 5%, respectively; both p<0.0001) and IGA response of clear or almost clear (84% versus 53% and 5%; both p<0.0001).

Source:

The Lancet